KZIA
Income statement / Annual
Last year (2024), Kazia Therapeutics Limited's total revenue was $2.31 M,
an increase of 415,755.86% from the previous year.
In 2024, Kazia Therapeutics Limited's net income was -$26.78 M.
See Kazia Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$2.31 M
|
$555.00
|
$25.00
|
$15.18 M
|
$1,061.00
|
$1,565.00
|
$13,108.00
|
$8.79 M
|
$4.07 M
|
$89,000.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$2.31 M |
$555.00 |
$25.00 |
$15.18 M |
$1,061.00 |
$1,565.00 |
$13,108.00 |
$8.79 M |
$4.07 M |
$89,000.00 |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$17.38 M
|
$15.56 M
|
$20.25 M
|
$14.54 M
|
$9.49 M
|
$6.48 M
|
$9.77 M
|
$11.14 M
|
$9.89 M
|
$5.94 M
|
| General & Administrative
Expenses |
$13.56 M
|
$8.58 M
|
$4.51 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$127,043.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.56 M
|
$8.58 M
|
$4.64 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
| Other Expenses |
-$28.64 M |
-$22,558.00 |
-$10,000.00 |
$0.00 |
-$22,000.00 |
-$9,000.00 |
$3.67 M |
$0.00 |
$2.87 M |
$1.54 M |
| Operating Expenses |
$2.31 M |
$24.12 M |
$24.88 M |
$24.13 M |
$13.16 M |
$10.25 M |
$14.69 M |
$19.66 M |
$15.64 M |
$9.68 M |
| Cost And Expenses |
$2.31 M |
$24.12 M |
$24.88 M |
$24.13 M |
$13.16 M |
$10.25 M |
$14.69 M |
$19.66 M |
$15.64 M |
$9.68 M |
| Interest Income |
$12,000.00 |
$22,558.00 |
$2,094.00 |
$42,240.00 |
$66,000.00 |
$100,000.00 |
$119,000.00 |
$276.00 |
$406,000.00 |
$89,261.00 |
| Interest Expense |
$0.00 |
$0.00 |
$2,094.00 |
$0.00 |
$0.00 |
$2.19 M |
$0.00 |
$0.00 |
$0.00 |
$68,621.00 |
| Depreciation &
Amortization |
$1.87 M
|
$1.87 M
|
$1.87 M
|
$1.27 M
|
$1.08 M
|
$1.08 M
|
$1.55 M
|
$1.41 M
|
$642,641.00
|
$574,964.00
|
| EBITDA |
-$26.77 M
|
-$22.28 M
|
-$23.51 M
|
-$5.11 M
|
-$11.11 M
|
-$7.71 M
|
-$10.82 M
|
-$9.44 M
|
-$11.72 M
|
-$7.48 M
|
| EBITDA Ratio |
-11.6 |
-40138.86 |
-989733.08 |
-0.34 |
-10783.22 |
-4661.98 |
-1349.86 |
-1.07 |
-2.88 |
-84.02 |
| Operating Income Ratio
|
0
|
-43466.61
|
-1067853.08
|
-0.42
|
-11804.9
|
-5354.63
|
-952.62
|
-1.23
|
-3.14
|
-91.47
|
| Total Other
Income/Expenses Net |
-$27.05 M
|
$3.39 M
|
$0.00
|
-$2.53 M
|
-$569,576.00
|
-$1.75 M
|
$6.02 M
|
$7,870.00
|
$227,965.00
|
$754,786.00
|
| Income Before Tax |
-$27.05 M |
-$20.74 M |
-$25.02 M |
-$8.91 M |
-$12.77 M |
-$10.57 M |
-$6.34 M |
-$10.87 M |
-$12.16 M |
-$7.31 M |
| Income Before Tax Ratio
|
-11.72
|
-37362.65
|
-1000635.8
|
-0.59
|
-12031.1
|
-6752.72
|
-483.98
|
-1.24
|
-2.99
|
-82.09
|
| Income Tax Expense |
-$271,000.00 |
$271,092.00 |
-$368,080.00 |
$484,347.00 |
-$298,000.00 |
-$298,000.00 |
-$305,000.00 |
$198,544.00 |
$2.77 M |
$1.44 M |
| Net Income |
-$26.78 M |
-$20.47 M |
-$24.65 M |
-$8.42 M |
-$12.47 M |
-$10.27 M |
-$6.04 M |
-$10.67 M |
-$12.06 M |
-$7.14 M |
| Net Income Ratio |
-11.6 |
-36874.2 |
-985912.6 |
-0.55 |
-11750.24 |
-6562.3 |
-460.71 |
-1.21 |
-2.96 |
-80.21 |
| EPS |
0 |
-1.12 |
-1.86 |
-0.0716 |
-1.71 |
-1.79 |
-1.25 |
-2.28 |
-2.82 |
-2.99 |
| EPS Diluted |
0 |
-1.11 |
-1.86 |
-0.0716 |
-1.71 |
-1.79 |
-1.25 |
-2.28 |
-2.82 |
-2.99 |
| Weighted Average Shares
Out |
$0.00
|
$18.22 M
|
$13.25 M
|
$117.63 M
|
$7.31 M
|
$5.75 M
|
$4.84 M
|
$4.68 M
|
$4.27 M
|
$2.38 M
|
| Weighted Average Shares
Out Diluted |
$0.00
|
$18.43 M
|
$13.25 M
|
$117.67 M
|
$7.31 M
|
$5.75 M
|
$4.84 M
|
$4.68 M
|
$4.27 M
|
$2.38 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
